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Abstract: Transition-metal catalyzed reactions have the 
potential to provide significant improvements to the syntheses 
of complex target molecules. These reactions can be used to 
achieve a variety of different atom-economical transformations 
and cascade reactions and therefore provide access to synthetic 
strategies that would otherwise be unavailable using classical 
organic chemistry. To exemplify the utility of the latest 
transition metal catalyzed reactions for the construction of 
important target structures, we have been involved in total 
synthesis of natural products bearing widely known chemical 
scaffolds. In this account, we report our recent studies on the 
use of a palladium-catalyzed cascade cyclization reaction and a 
gold(I)-catalyzed hydroamination reaction, for the construction 
of the core structures of alkaloids, as well as their application to 
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1 Introduction 
Making improvements to the step and atom 
economies of organic transformations is one of the 
most important requirements in modern organic 
chemistry.1 Transition metal catalysts have had a 
significant impact on the facility with which organic 
chemists can access complex target structures by 
providing synthetic strategies for the construction of 
target molecule that would otherwise be difficult or 
even impossible to access using classical organic 
chemistry. To demonstrate the power of transition 
metal catalysis in organic chemistry, we have been 
working towards the synthesis of natural products 
using transition-metal-catalyzed cyclization reactions. 
A series of well-known chemical scaffolds were 
selected as the targets of our study including those of 
the ergot alkaloids (e.g., lysergic acid, lysergol, and 
isolysergol) and the tetrahydroisoquinoline alkaloids 
(e.g., quinocarcin). Although several efficient total 
syntheses of these natural products have already been 
reported (for details, see the introduction text of 
sections 2 and 3), our current approach represents a 
unique strategy that sometimes provide improvements 
in the step and atom economies of the syntheses of 
these compounds, as well as providing a platform for 
the synthesis of other complex natural products. 
Herein, we describe our recent work towards the 
synthesis of ergot alkaloids using a palladium-
catalyzed cascade cyclization of allenes, as well as a 
gold(I)-catalyzed hydroamination for the synthesis of 
tetrahydroisoquinoline alkaloids. 














































Figure 1 Indole alkaloids of the ergot family and their synthetic 
derivatives. 
The ergot family of alkaloids consists of several 
pharmacologically important fused indoles, including 
lysergic acid (1), lysergol (2), and isolysergol (3) 
(Figure 1). Compounds belonging to this particular 
family are produced by the fungus Claviceps purpurea, 
which grows parasitically on rye and other grains,2 
and have been reported to possess a variety of 
different biological activities. For example, pergolide 
and bromocriptine, which are synthetic derivatives of 
the ergot alkaloids, are clinically used as anti-prolactin 
and anti-Parkinson’s disease drugs, respectively.3 
Lysergic acid diethylamide (LSD) is well known as a 
strong psychoactive agent. The characteristic 
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structural feature of these alkaloids is their tetracyclic 
fused indole, which contains a Δ9,10-double bond and 
chiral centers at the C5 and C8 positions.  
Ergot alkaloids, especially lysergic acid, have been the 
target of many synthetic studies because of their 
biological importance as well as their structural 
complexity. The first total synthesis of racemic 
lysergic acid was accomplished by Woodward in 
1956.4a Several racemic syntheses of ergot alkaloids 
have subsequently been reported,4,5 with most of the 
strategies involving the stepwise and linear 
construction of the C/D ring system. One important 
exception, however, is the strategy described by 
Oppolzer,4d which involved the simultaneous 
construction of the C/D rings through an 
intramolecular imino-Diels–Alder reaction. The 
asymmetric total synthesis of lysergic acid was first 
reported in 2004 by Szántay and coworkers,6a which 
involved the resolution of a racemic tetracyclic 
intermediate using dibenzoyl-L-tartaric acid. In 2009, 
Fukuyama et al. reported the asymmetric synthesis of 
the methyl ester of lysergic acid using a Heck 
cyclization reaction6b or palladium-catalyzed double-
cyclization (N-arylation and Heck reaction).6c More 
recently, Jia6e reported the asymmetric total synthesis 
of lysergic acid using a RCM reaction as the key step. 
This particular report was published after our own 
report (vide infra).6d  
Based on our recent studies towards palladium-
catalyzed cascade cyclization reactions, we designed a 
novel strategy for the construction of the core 
structure of ergot alkaloids that could be used for the 
asymmetric total synthesis of lysergic acid (1), 
lysergol (2), and isolysergol (3). 
2.1 Construction of the Core Structure of the 
Ergot Alkaloids using a Palladium-
Catalyzed Cascade Cyclization4j  
It is well known that arylpalladium halides generated 
in situ from the reaction of aryl halides with 
palladium(0), can regioselectively react with allenes to 
form 3-allylpalladium(II) intermediates (Scheme 
1).7,8 In 2003, we reported the direct formation of the 
tricyclic isoindole derivatives 5 from allenes 4 using 
an alkene carbopalladation reaction followed by a 
direct arylation/C-H bond functionalization (7 to 8) 
(Scheme 2).9 The reaction of 4 with heterocyclic aryl 
halides provided direct access to the corresponding tri- 
and tetracyclic heteroaromatic products. More recently, 
we reported a fully intramolecular cascade cyclization 
reaction using amino allene derivatives,10 with similar 
results also being reported by some other groups.11,12 
For example, the reaction of 9 under these conditions 
terminates with the nucleophilic attack of a protected 











Scheme 1 General Scheme for Palladium-Catalyzed Reaction of 


































Scheme 2 Palladium-Catalyzed Cascade Cyclization of Allenene 


















Scheme 3 Palladium-Catalyzed Fully Intramolecular Cascade 
Cyclization of Amino Allene Derivatives. 
In light of this chemistry, it was envisaged that the 
palladium-catalyzed cascade cyclization of amino 
allenes 12 bearing a protected 4-bromoindol-3-yl 
group (Scheme 4) would provide direct access to 
tetracyclic indoles 11 bearing the core structure of the 
ergot alkaloids. The development of such a strategy 
for the construction of the desired 6,6-fused C/D ring 
system would be challenging, because the reaction of 
an internal allene bearing an aryl halide and amino 
group at both ends was unprecedented.10-12 The allene 
unit of 12 could be constructed via the Claisen 
rearrangement of the propargyl enol ether 13, which 
could be readily obtained through the conjugate 





























Scheme 4 Retrosynthetic Analysis of the Racemic Cyclization 
Precursor 12. 
Racemic allenic amide 19 was prepared as a model 
compound to evaluate the overall scope of our 
strategy for the construction of the core structure of 
ergot alkaloids (Scheme 5). Commercially available 4-
bromoindole (15) was readily converted to the 
protected 3-(bromomethyl)indole (16) via the 
formylation of the indole at the 3-position, followed 
by sequential N-tosylation, reduction of the 3-formyl 
group, and the bromination of the resulting primary 
hydroxy group. The addition of lithiated 1,3-dithiane13 
to 16, followed by hydrolysis of the thiacetal,14 and 
subsequent reduction of the resulting ketone gave 
racemic propargyl alcohol 17. The propargyl vinyl 
ether 18 was then obtained via the conjugate addition 
of 17 to methyl propiolate,15 followed by sequential 
DIBAL reduction of the resulting enolate and TIPS 
protection of the resulting alcohol. The Claisen 
rearrangement of 18 under thermal conditions (m-
xylene, 170°C) did not proceed as anticipated and 
gave the desired allenic alcohol (dr = ca. 33:67) in a 
low yield of only 38%. Pleasingly, however, the use of 
5 mol% of the gold-oxo complex [(Ph3PAu)3O]BF416 
gave the rearrangement product in 78% yield 
following the reduction of the aldehyde with NaBH4 
(dr = ca. 80:20, favoring the opposite diastereomer to 
the thermal conditions). A Mitsunobu reaction with 
NsNH2 gave the allenic nosylamide derivative 19 as a 
mixture of diastereomers (dr = 80:20), which was 
progressed directly into the subsequent step without 
separation. The corresponding tosylamide derivative 
20 (dr = ca. 80:20) (Scheme 6) was also prepared in a 
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Scheme 5 Synthesis of the Racemic Cyclization Precursor 19 by a 
Gold-Catalyzed Claisen Rearrangement 
We then proceeded to investigate the construction of 
the ergot alkaloid skeleton using the palladium-
catalyzed cascade cyclization (Scheme 6). Among the 
different palladium catalysts [Pd(OAc)2/PPh3, 
PdCl2(dppf), Pd(OAc)2/P(o-tol)3 and Pd(OAc)2/rac-
BINAP], bases (Na2CO3, Cs2CO3, and K2CO3), and 
solvents (DMF, DMSO, toluene, and dioxane) tested, 
a combination of 5 mol% of Pd(PPh3)4 with K2CO3 in 
DMF was found to be the most effective, and gave the 
desired tetracyclic indole 21 in 83% yield as a 73:27 
stereoisomeric mixture. When the N-tosyl derivative 
20 was subjected to the optimized reaction conditions, 
the desired product 22 was isolated in 65% yield with 
good diastereoselectivity (87:13). The decision was 
taken to use the tosylamide as the cyclization 
precursor for our asymmetric total syntheses in the 
current study because of the stereoselectivity and ease 
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Scheme 6 Construction of the Ergot Alkaloid Core Structure Using 
the Palladium-Catalyzed Cascade Cyclization 
The different diastereomers of the allene were 
carefully separated by HPLC and subjected to the 
cascade cyclization conditions to develop a deeper 
understanding of the reaction mechanism (Scheme 7). 
The major isomer 19a gave an 83:17 mixture of 
isomers in 78% yield, with 21a being isolated as the 
major cyclized product, as anticipated. In contrast, the 
minor isomer 19b gave the other diastereomer 21b 
(a:b = 21:79) as the major product in a combined 
yield of 67% yield. These results can be understood in 









from 19a: 78% (21a:21b = 83:17)























Scheme 7 The Cascade Cyclization of Each Diastereomer 
It can be difficult to predict the product distribution of 
the palladium-catalyzed cyclization of amino allenes 
with an aryl halide,18 because reactions of this type 
can proceed via the two competing major pathways, 
including (a) the aminopalladation19 and (b) 
carbopalladation20 pathways (Scheme 8). In the 
aminopalladation pathway, the arylpalladium halide 
activates the distal double bond of the amino allene 23 
from the least hindered side and promotes an endo-
type cyclization (eq 1), with nitrogen heterocycle 25a 
being formed stereospecifically via a reductive 
elimination step. The occurrence of an 
aminopalladation reaction at the proximal double 
bond would give its regioisomer 27 (eq 2). In contrast, 
carbopalladation onto the distal double bond from the 
least hindered side of the double bond would give the 
1-allylpalladium(II) intermediate 28, which would 
lead to the 3-intermediates 29a and 29b through 
isomerization. Subsequent intramolecular anti-
cyclization would then give the endo-cyclization 
product 25a (eq 3) and/or the exo-cyclization product 
27 (eq 4). These are the same products as those 
formed from the distal and proximal bond 
aminopalladation pathways (eqs 1 and 2). It is 
noteworthy that the cyclization product 25b, formed 
through a carbopalladation at the proximal double 
bond followed by an endo-cyclization (eq 5), has the 
opposite configuration to the distal aminopalladation 
product 25a (eq 1). The exo-type cyclization product 
27 could also be formed from the 3-allylpalladium 
intermediates 29d (eq 6), which makes it particularly 























































































Scheme 8 General Reaction Pathways for the Palladium-Catalyzed 
Reaction of Amino Allenes with Arylpalladium Halides 
In our case, aminopalladation at the distal double 
bond (as in eq 1 of Scheme 8 to form 25a) adequately 
explains the formation of the major isomer 21a from 
the amino allene 19a (Scheme 9). Coordination of the 
indolylpalladium(II) to the allenic moiety would 
promote anti-attack of the sulfonamide group as 
shown in 31. Aminopalladation from the favored 
conformation would generate the seven-membered 
palladacycle 32, and subsequent reductive elimination 
would give the major isomer 21a. In contrast, 
carbopalladation at the proximal double bond (as in eq 
5 of Scheme 8 to form 25b) would rationalize the 
formation of the minor isomer 21b, with a steric effect 
in the carbopalladation of indolylpalladium(II) 
bromide allowing for the carbopalladation to proceed 
onto the proximal double bond, as depicted in 33, to 
generate the 3-allylpalladium complex 34. The 
second cyclization resulting from the sulfonamide 
group would then occur in an anti-manner to give the 
minor isomer 21b. The formation of 21a as the major 
product can be explained in terms of the strained 








































Scheme 9 Possible Pathways to 21a and 21b via Aminopalladation 
and Carbopalladation 
2.2 Asymmetric Total Synthesis of (+)-
Lysergic Acid and Related Alkaloids6d  
We then proceeded to investigate the asymmetric total 
synthesis of ergot alkaloids using the established 
cascade cyclization conditions for the construction of 
their core structure. In light of the difficulties that we 
experienced controlling the stereoselectivity of the 
Claisen rearrangement of propargyl enol ether 18 
(Scheme 5), we made changes to the synthetic route 
used to access the amino allene. As shown in Scheme 
10, it was envisaged that the chiral allene unit of 35a 
could be constructed from enantiomerically enriched 
propargyl alcohol 36a using the method reported by 
Myers.21 The propargyl alcohol 36a could be obtained 
from the coupling of aldehyde 37 with alkynes 38. If 
necessary, oxidation and asymmetric hydrogenation 
reactions could be used for asymmetric induction at 
the propargyl position. The alkynes 38 could be 
accessed from the known 2-ethynylaziridine 39,22 
which can be derived from L-serine via an indium(I)-
mediated reductive coupling reaction with 




























Scheme 10 Retrosynthetic Analysis of Enantiomerically Enriched 
Cyclization Precursor 35a  
The synthesis of the alkynes 38 is shown in Scheme 
11. Following our reported procedure,22 the 
enantiomerically enriched aziridine 39 (97% ee) was 
prepared from (S)-Garner’s aldehyde24 via sequential 
alkyne formation, deprotection, N-tosylation, and 
aziridine formation reactions. Treatment of the 
aziridine 39 with formalin under the InI-mediated 
reductive coupling condition [i.e., Pd(PPh3)4 (5 
mol %), InI, THF/HMPA (4:1)]23 gave the desired 1,3-
amino alcohol 38a (97% ee) in 88% yield. A single 
recrystallization afforded optically pure 38a (99% ee). 
The benzylidene acetal 38b and the corresponding 
iodoalkyne derivative 38c were prepared by the 
treatment of 38a with benzaldehyde 
dimethylacetal/CSA (followed by NIS/AgNO325 for 
38c). 
NTs






















Scheme 11 Preparation of the Alkyne Units 38. DCE = 1,2-
dichloroethane 
We next investigated the preparation of aldehyde 37 
and its cross-coupling reaction with the alkynes 38 
(Scheme 12). Commercially available 4-bromoindole 
40 was converted to 3-allylindole 41 using a 
palladium-catalyzed C3-selective allylation reaction 
with allyl alcohol and triethylborane,26 followed by N-
protection. OsO4/NaIO4-mediated oxidation of 41 
gave the desired aldehyde 37. Among the different 
methods available for the coupling of 37 and 38, 
including n-BuLi, n-BuLi/CeCl3,27 InBr3/(R)-
BINOL,28 and Et2Zn/(S)-BINOL/Ti(Oi-Pr)4,29 the 
Cr(II)/Ni(0)-mediated Nozaki−Hiyama−Kishi (NHK) 
reaction30 using iodoalkyne 38c was found to be the 
most efficient procedure, resulting in formation of the 
desired coupling product in 90% yield (dr = 1:1). 
Unfortunately, subsequent attempts to carry out the 
asymmetric NHK reaction31 failed to produce the 
desired propargyl alcohol, and an isomeric mixture of 
the propargyl alcohol was therefore oxidized to 42 and 
subjected to an (R)-Alpine-borane-mediated 
asymmetric reduction32 to afford the propargyl alcohol 
36a with high diastereoselectivity (dr = >95:5). 
Finally, the allenic amide 35a was obtained from 36a 
according to the method reported by Myers,21 with 
nosyl hydrazine being used under Mitsunobu 
conditions followed by the cleavage of the 
benzylidene group. The diastereomeric allenic amide 
35b (Scheme 13) was prepared in a similar manner 
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Scheme 12 Stereoselective Synthesis of the Enantiomerically 
Enriched Cyclization Precursor 35a. DMP = Dess–Martin 
periodinane. 
The construction of the ergot alkaloid skeleton via the 
palladium-catalyzed cascade cyclization of the allenic 
amides 35 bearing a free hydroxy group is shown in 
Scheme 13. The reaction of 35a (94:6 isomeric 
mixture) under the optimized conditions, which were 
developed above for the cascade cyclization of the 
racemic model substrates 19 and 20 bearing a silyl 
ether moiety (Scheme 6), provided the desired product 
43 in 76% yield. The diastereomeric allenic amide 
35b afforded the cyclization products 43a and 43b, 
although the reaction was not as efficient or 
stereoselective (43% yield, 43a:43b = 31:69). Once 
again, these results reveal the differences in the 











from 35a: 76% (43a:43b = 92:8)






















Scheme 13 Cascade Cyclization of 35 
With the tetracyclic indole 43a in hand with all of the 
requisite functionalities, we proceeded to investigate 
the total synthesis of the ergot alkaloids. A simple 
two-step procedure for the conversion of 43a to 
isolysergol (3) is shown in Scheme 14. Removal of 
the tosyl groups of 43a with sodium naphthalenide 
and subsequent N-methylation followed by separation 
of the diastereomers gave (+)-isolysergol (3) in 46% 










43a (dr = 92:8)
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Scheme 14 Total Synthesis of (+)-Isolysergol (3) 
The syntheses of lysergic acid and lysergol from 43a 
would require the inversion of the stereochemistry at 
the 8-position, and this was accomplished by the 
epimerization of the corresponding ester derivatives 
(Scheme 15). Thus, the two-step oxidation of the 
primary alcohol in 43a followed by esterification with 
TMSCHN2 gave the corresponding methyl ester 44a 
(64%, 3 steps). It was important to separate the 
diastereomers (derived from the chirality at the C-5 
position) at this step for the preparation of lysergic 
acid (1) and lysergol (2) in high ee, because the 
successful conversion of 44a to 1 and 2 through 
isomerization would rely on the chiral information 
conveyed from the C-5 position. Cleavage of the two 
tosyl groups and subsequent reductive N-methylation 
led to a mixture of methyl isolysergate 45a and 
lysergate 45b (65% yield, 45a:45b = 33:67). 
Reduction of this mixture with LiAlH4 produced (+)-
lysergol (2) in 49% yield (98% ee, Chiralcel OD-H), 
together with (+)-isolysergol (3) (24%).33 Finally, the 
lysergate 45 (45a:45b = 33:67) was converted to (+)-
lysergic acid (1) in 54% yield (96% ee, Chiralcel OD-
H after methylation with TMSCHN2)34 by hydrolysis 
with NaOH with concomitant isomerization.6a All of 
the spectroscopic data collected for the synthesized 
compounds 1, 2, and 3 were in agreement with those 
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Scheme 15 Total Syntheses of (+)-Lysergic Acid (1) and (+)-
Lysergol (2) 
3 Quinocarcin Synthesis 
(–)-Quinocarcin (46), which was originally isolated 
from the culture of Streptomyces melanovinaceus, is a 
pentacyclic tetrahydroisoquinoline alkaloid with 
antiproliferative activity against lymphocytic 
leukemia (Figure 2).35 This particular compound is 
structurally similar to tetrazomine and lemonomycin, 
in that it shares a common skeleton composed of a 
piperizinohydro-isoquinoline motif. Saframycin and 
ecteinascidin 743 (Et-743, Yondelis®) differ in terms 
of their D-ring, which is a six-membered ring.36 Some 
of these compounds have been report to display 
similar antitumor and antibiotic activities, with Et-743 
in particular exhibiting high levels of activity towards 
a broad range of tumor cell lines at sub-nanomolar 
concentrations.37 The development of a divergent 
synthetic route to this class of compounds would 
therefore be of considerable value for drug discovery.  
The potent biological properties and challenging 
molecular architectures of these compounds have led 
to the development of several different creative 
approaches for their total syntheses.36,38-40 Most of the 
methods reported in this area, however, were designed 
for the specific synthesis of one of these compounds, 
with the Pictet–Spengler condensation reaction being 
used in the majority of cases for the construction of 
the isoquinoline core structure.[38,39e,f,40] In the interest 
of developing a novel, general and convergent 
strategy capable of providing access to several 
different tetrahydroisoquinolines, we designed a 
unique method for the construction of the core 
structure of the tetrahydroisoquinoline alkaloids core 









































































Figure 2 Quinocarcin and related tetrahydroisoquinoline alkaloids 
3.1 Construction of the Core Structure by 
Gold-Catalyzed Alkyne 
Hydroamination39h,i  
Intramolecular alkyne hydroamination catalyzed by a 
transition metal complex provides atom-economical 
and straightforward access to nitrogen-containing 
heterocycles.41 Recent progress in homogeneous gold 
catalysis has revealed that cationic gold complexes are 
extremely useful for alkyne hydroamination reactions, 
which can afford the desired addition products under 
mild reaction conditions.42 
We recently reported the direct synthesis of 2-
(aminomethyl)indoles 48 and related compounds via a 
copper-catalyzed three-component Mannich-type 
coupling reaction between protected 2-ethynylanilines 
47, aldehydes, and secondary amines followed by an 
intramolecular hydroamination (Scheme 16).43 The 
use of 2-ethynylbenzaldehyde 49 as a starting material 
under these conditions provided access to 
isoquinolines.44 We have also demonstrated that 
cationic gold catalysts promote the cascade 
cyclization of diynylaniline derivatives 51 to form 
fused carbazoles 52.45,46 This transformation 
proceeded through an alkyne hydroamination reaction 
to form the indole ring followed by an alkyne 
hydroarylation. 
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Scheme 16 Transition-Metal-Catalyzed Alkyne Hydroamination 
Reported by Our Group 
Based on these studies, we design a novel a strategy 
aimed at providing access to the quinocarcin-type core 
structure through a transition-metal-catalyzed 
hydroamination. Our retrosynthetic analysis of (–)-
quinocarcin (46) is shown in Scheme 17. It was 
envisaged that quinocarcin could be obtained from 
lactam 53 following the procedures reported by Zhu39f 
and Stoltz.39g This lactam could be synthesized via the 
hydrogenation of enamine 54 followed by an 
intramolecular amide formation. The enamine 54 
could be accessed according to the intramolecular 
hydroamination of alkyne 55, which could be readily 
prepared by the Sonogashira coupling reaction of the 
iodinated phenylglycinol derivative 56 and 2-
alkynylpyrrolidine 57. It was also envisaged that the 
bromoallene cyclization reaction previously reported 
by our group47 could be used for the stereocontrolled 
construction of the 2,5-cis-pyrrolidine 57. This 
synthetic strategy was particularly attractive because 
different quinocarcin derivatives and other related 
alkaloids could potentially be obtained by simply 
changing the coupling components 56 and 57 during 



























































Scheme 17 Retrosynthetic Analysis of (–)-Quinocarcin 
Control of the regioselectivity in the hydroamination 
of 55 would be critical to the success of this particular 
strategy. Thus, a 5-exo-dig cyclization would lead to 
the formation of the undesired isoindoline-type 
product 59 (Scheme 18), whereas a 6-endo-dig 
cyclization would afford the desired 
dihydroisoquinoline 54 required for the synthesis of 
quinocarcin. The 5-exo-dig cyclization could be 
predominated, however, because transition-metal-
catalyzed C–N bond formation reactions generally 
occur at the more cationic carbon atom of activated 
alkynes bearing an aryl substituent. With this in mind, 
our initial work involved the use of a model study to 















Scheme 18 Regioselectivity Issue in the Alkyne Hydroamination 
The reaction of the model substrates 60a, which was 
readily prepared by the Sonogashira coupling of the 
racemic an aryl iodide with a propargyl amine, is 
shown in Scheme 19. Disappointingly, the 
hydroamination of 60a using a variety of different 
transition-metal catalysts, including Au(I), Cu(I), 
Pt(II), In(III), and Rh(I) favored the 5-exo-dig 












60a: R = 
R' = H or OMe
61a (0–6%) 62a (21–74%)NMe O
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(R' = Me or t-Bu)
 
Scheme 20 Substrate-Controlled 6-endo-dig Hydroamination 
The decision was then taken to modify the substrate 
structure (Scheme 20). Improvements in the 
regioselectivity were observed when the seven-
membered acetonide-type substrates 60b and 60c 
were treated with the gold catalyst A, with the desired 
6-endo-dig products 61b (61%) and 61c (31–37%), 
respectively, being isolated in moderate yields. It was 
envisaged that the destabilization of the 5-exo-dig 
product would lead to further improvements in the 
regioselectivity. With this in mind, we proceeded to 
examine the reaction of dihydrobenzofuran-type 
substrate 60d. In this particular case, the desired 6-
endo-dig product 61d was obtained exclusively in 
73% yield. The gold catalyst B has proven to be 
highly active, affording 61d in 96% yield. These 
model experiments therefore revealed that the 
phenylglycinol derivative 56 (Scheme 17) could be 
used as the target building block for the synthesis of 
quinocarcin as the corresponding dihydrobenzofuran-
type aryl iodide. 
3.2 Asymmetric Total Synthesis of (–)-
Quinocarcin39h,i  
With an optimized procedure in hand for controlling 
the regioselectivity of the alkyne hydroamination 
reaction, we proceeded to investigate the preparation 
of the optically active dihydrobenzofuran (R)-56a 
(Scheme 21). Formylation of 3-fluoroiodobenzene 63 
with LDA and DMF followed by the Wittig reaction 
of the resulting aldehyde afforded the dihalostyrene 64. 
Subsequent Sharpless asymmetric dihydroxylation48 
of 64 and a single recrystallization provided the 
optically pure diol 65 (>99% ee), which was 
converted to the desired dihydrobenzofuran derivative 
(R)-56a via the introduction of an azide group with 
DPPA under Mitsunobu conditions,49 followed by an 
intramolecular SNAr reaction to form the dihydrofuran 
ring using t-BuOK, reduction of the azide group with 


































1) TBSCl, DMAP, Et3N, CH2Cl2
2) DPPA, DEAD, PPh3, THF3) TBAF, THF
(86%, 3 steps)
t-BuOK, THF




Scheme 21 Preparation of the Optically Active Dihydrobenzofuran 
(R)-56a. (DHQ)2PHAL = hydroquinine 1,4-phthalazinediyl 
diether; DPPA = diphenylphosphoryl azide. 
The preparation of the 2,5-cis-pyrrolidine 57 using the 
bromoallene cyclization is shown in Scheme 22. The 
diastereoselective propargylation of -butyrolactone 
68 gave the corresponding addition product 69, which 
was reduced with LiBH4 followed by selective 
acetylation of the primary hydroxy group to give 
alcohol 70. Mitsunobu reaction with TsBocNH was 
then used to introduce the required nitrogen 
functionality, followed by selenium oxidation to give 
the propargyl alcohol 71 as a mixture of diastereomers. 
The bromoallene 58a (dr = 55:45) was then formed 
using a standard protocol involving the sequential 
mesylation and bromination reactions with 
CuBr·SMe2/LiBr.51 As expected, the treatment of 58a 
with NaH in DMF led to a stereoselective pyrrolidine 
formation to afford the desired 2,5-cis-72 in 95% yield 
(2,5-cis:trans = 96:4). It is noteworthy that the 
intramolecular SN2 reaction using mesylate 74 derived 
from 71 under identical reaction conditions afforded 
72 as a mixture of diastereomers (2,5-cis:trans = 
55:45) in a ratio corresponding to that of the mesylate 
74 (Scheme 23). Thus, the mesylate-to-bromoallene 
conversion is important in terms of controlling the 
2,5-cis-selectivity. The desired pyrrolidine 57 for the 
Sonogashira coupling was then prepared from 2,5-cis-
72 according to sequential oxidation, esterification, 
and N-methylation reactions using standard protocols. 
DMF, 20 °C
(95%) 2,5-cis-72





















































2) K2CO3, MeOH3) DMP, CH2Cl2
4) NaClO2, 2-methylbut-2-eneNaH2PO4·2H2O






Scheme 22 Preparation of the Optically Active Pyrrolidine 57 via 
Bromoallene Cyclization. EDC = N-(3-dimethylaminopropyl)-N’-
















Scheme 23 Cyclization of Mesylate 74. 
We then moved on to investigate the coupling of the 
two building blocks (R)-56a and 2,5-cis-57, and the 
construction of the quinocarcin core structure 
(Scheme 24). The treatment of an equimolar mixture 
of the two components with Pd(PPh3)4, CuSO4, and 
sodium ascorbate52 gave the coupling product 55a in 
92% yield. Our initial attempt at the gold-catalyzed 
hydroamination using 55a, however, was not as 
efficient, and gave the desired product in up to 46% 
yield using 40 mol% of cat. A (see Scheme 20). The 
lower yield observed in this case was attributed to 
unfavorable steric repulsion between the methyl ester 
at the C-5 position of the pyrrolidine and the N-Boc 
group in the conformer required for the 
hydroamination reaction. In contrast, the reaction of 
the corresponding amine 55b proceeded more 
efficiently upon treatment with cat. A. Following the 
stereoselective reduction of the unstable 
hydroamination product with NaBH3(CN), the 
tetrahydroisoquinoline 75 was isolated in 90% yield. 
As expected, the secondary amine selectively 
underwent lactam formation with one of the ester 
groups when 75 was heated in the presence of AcOH, 
leading to 53a with the diazabicyclo[3.2.1]octane core 
structure in 96% yield. 
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[]27D = –27.1° (c 0.11, H2O)lit. []22D = –31.6° (c 0.28, H2O)




1) cat. A (20 mol %)
DCE, 45 °C












55a: R = Boc




2) AgNO3, Et3N, acetone/H2O (3:1)









Scheme 24 Total Synthesis of Quinocarcin 
The remaining task of affecting the unusual 
dihydrobenzofuran cleavage required thorough 
investigation. Based on the ring-opening iodination 
reaction of dihydrobenzofuran with LiI in the presence 
of SiCl4 and BF3·AcOH reported by Zewge et al.,53 
we investigated the ring-opening reaction of 53a 
assisted by the neighboring lactam carbonyl group.54 
It was envisaged that the treatment of lactam 53a with 
the Lewis acids (in the absence of LiI) would afford 
the oxazolidinium intermediate 76, which could be 
captured through an appropriate workup procedure. 
Unfortunately, however, the exposure of 53a to 
BF3·Et2O and SiCl4 in DCE followed by an aqueous 
workup of the resulting suspension (presumably 
containing 76) only resulted in the recovery of the 
starting material 53a. The failure of the reaction in 
this particular case was attributed to the hydrolysis of 
the transient silyl ether in 76 prior to the required 
cleavage of the oxazolidinium, which effectively 
promoted the reverse reaction from 76 to 53a. 
Following a period of extensive experimentation using 
a variety of different Lewis acids, as well as 
investigating the capture of 76 through silane 
reduction and amidine formation, we found that the 
addition of an excess of CsCl to the reaction mixture 
after the ring-opening reaction gave the chlorinated 
phenol 77 containing the quinocarcin core structure in 
92% yield. Subsequent conversion of 77 to the known 
amide 53b was achieved by the methylation of the 
phenol followed by hydrolysis of the carbon-chlorine 
bond in the presence of AgNO3 and Et3N. The total 
synthesis of quinocarcin was then completed using the 
procedure reported by Allan and Stoltz.39g The 
spectroscopic data for our synthetic (–)-quinocarcin 
were identical to those reported.35,39  
3 Concluding Remarks 
The work described herein demonstrates the enormous 
potential associated with the latest transition-metal 
catalyzed reactions for the synthesis of complex 
alkaloids. The highlights of the current work include 
the palladium-catalyzed cascade cyclization of allenes 
for the synthesis of ergot alkaloids and the gold(I)-
catalyzed hydroamination of alkynes for the synthesis 
of the tetrahydroisoquinoline alkaloid, quinocarcin. 
These examples show that the use of transition-metal 
catalyzed reactions can provide a platform for the 
development of novel synthetic approach towards a 
range of different alkaloids, containing the important 
structural elements, and possibly lead to better 
synthetic access to alkaloid derivatives that would 
otherwise be difficult to obtain using conventional 
organic chemistry. 
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